Indirect Sertoli cell-mediated ablation of germ cells in mice expressing the inhibin-alpha promoter/herpes simplex virus thymidine kinase transgene.
In the present study, we describe a novel mouse model for inducible germ cell ablation. The mice express herpes simplex virus thymidine kinase (HSV-TK) under the inhibin-alpha subunit promoter (Inhalpha). When adult transgenic (TG) mice were treated with famciclovir (FCV) for 4 wk, their spermatogenesis was totally abolished, with only Sertoli cells and few spermatids remaining in the seminiferous tubules. However, testicular steroidogenesis was not affected. Shorter treatment periods allowed us to follow up the progression of germ cell death: After 3 days, spermatogonia and preleptotene spermatocytes were no longer present. After a 1-wk treatment, spermatogonia, preleptotene, and zygotene spermatocytes were missing and the amount of pachytene spermatocytes was decreased. After a 2-wk treatment, round and elongating spermatids were present. During the third week, round spermatids were lost and, finally, after a 4-wk treatment, only Sertoli cells and few spermatids were present. Interestingly, the transgene is detected in Leydig and Sertoli cells but not in spermatogonia. This suggests that FCV is phosphorylated in Sertoli cells, and thereafter, leaks to neighboring spermatogonia, apparently through cell-cell junctions present, enabling trafficking of phosphorylated FCV. Because of the many mitotic divisions they pass through, the spermatogonia are very sensitive to toxins interfering with DNA replication, while nondividing Sertoli cells are protected. Using transillumination-assisted microdissection of the seminiferous tubules, the gene-expression patterns analyzed corresponded closely to the histologically observed progression of cell death. Thus, the model offers a new tool for studies on germ cell-Sertoli cell interactions by accurate alteration of the germ cell composition in seminiferous tubules.
Ahtiainen
Maarit
M
Department of Physiology, University of Turku, FIN-20520 Turku, Finland.
Toppari
Jorma
J
Poutanen
Matti
M
Huhtaniemi
Ilpo
I
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology; D000077595:Famciclovir; D015870:Gene Expression; D007265:Inhibins / Q000235:genetics*; D007985:Leydig Cells / Q000502:physiology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic / Q000235:genetics / Q000378:metabolism; D023421:Models, Animal; D011401:Promoter Regions, Genetic; D012671:Seminiferous Tubules / Q000378:metabolism; D012708:Sertoli Cells / Q000502:physiology*; D018139:Simplexvirus / Q000201:enzymology*; D013091:Spermatogenesis / Q000187:drug effects / Q000502:physiology*; D013937:Thymidine Kinase / Q000235:genetics / Q000378:metabolism*
D000998:Antiviral Agents; C094377:inhibin-alpha subunit; D015075:2-Aminopurine; D007265:Inhibins; D013937:Thymidine Kinase; D000077595:Famciclovir